Skip to content
  • Investors
  • Careers
  • Contact Us
  • TW
  • LI
  • WC
Apollomics Pharmaceuticals
  • Our Company
    • About Us
    • Management
    • Board of Directors
    • Our Partners
    • Apollomics China
    • Contact
  • Our Science
    • Our Approach
    • Publications
  • Our Pipeline
    • R&D Pipeline
    • Vebreltinib (APL-101)
    • Uproleselan (APL-106)
    • APL-102
    • APL-501
  • Investors
  • News/Events
    • Press Releases
    • Events & Presentations
    • Community
  • Contact
  • English
    • 简体中文
×
  • Our Company
    • About Us
    • Management
    • Board of Directors
    • Our Partners
    • Apollomics China
    • Contact
  • Our Science
    • Our Approach
    • Publications
  • Our Pipeline
    • R&D Pipeline
    • Vebreltinib (APL-101)
    • Uproleselan (APL-106)
    • APL-102
    • APL-501
  • Investors
  • News/Events
    • Press Releases
    • Events & Presentations
    • Community
  • Contact
  • English
    • 简体中文
Apollomics Pharmaceuticals

our company
management
board of directors
our partners
apollomics china

our approach
publications

our pipeline
Vebreltinib (APL-101)
Uproleselan (APL-106)
APL-102)
APL-501

investors
investor relations

news & events
press releases
events
presentations

join our team
opportunities

contact us
Apollomics, Inc.
989 East Hillsdale Blvd. Ste 220
Foster City, CA 94404 USA
+1.650.209.4055 phone
+1.650.288.1674 fax

© 2025 Apollomics, Inc.  All Rights Reserved. • Privacy Policy

Our site uses cookies as described in our Privacy Policy. Please click Continue if you agree to the use of cookies on our site.